Lucira Health (NASDAQ:LHDXQ – Get Rating) is one of 42 public companies in the "Diagnostic substances" industry, but how does it compare to its peers? We will compare Lucira Health to related companies based on the strength of its institutional ownership, valuation, dividends, risk, profitability, analyst recommendations and earnings.
Analyst Ratings
This is a summary of recent ratings and target prices for Lucira Health and its peers, as reported by MarketBeat.com.
Get Lucira Health alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
| Lucira Health Competitors | 341 | 626 | 1235 | 19 | 2.42 |
As a group, "Diagnostic substances" companies have a potential upside of 37.76%. Given Lucira Health's peers higher possible upside, analysts plainly believe Lucira Health has less favorable growth aspects than its peers.
Risk and Volatility
Lucira Health has a beta of 3.36, meaning that its share price is 236% more volatile than the S&P 500. Comparatively, Lucira Health's peers have a beta of 1.38, meaning that their average share price is 38% more volatile than the S&P 500.
Profitability
This table compares Lucira Health and its peers' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucira Health | -67.54% | -13.55% | -8.47% |
| Lucira Health Competitors | -1,437.85% | -124.65% | -30.99% |
Valuation and Earnings
This table compares Lucira Health and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lucira Health | $93.06 million | -$64.83 million | -0.05 |
| Lucira Health Competitors | $466.17 million | $9.58 million | -52.37 |
Lucira Health's peers have higher revenue and earnings than Lucira Health. Lucira Health is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
57.0% of Lucira Health shares are owned by institutional investors. Comparatively, 45.4% of shares of all "Diagnostic substances" companies are owned by institutional investors. 30.4% of Lucira Health shares are owned by insiders. Comparatively, 14.1% of shares of all "Diagnostic substances" companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Lucira Health beats its peers on 7 of the 10 factors compared.
About Lucira Health
(Get Rating)
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.